bevacizumab + carboplatin + ixabepilone

This is a combination regimen consisting of three agents—bevacizumab, carboplatin, and ixabepilone—used primarily in the treatment of advanced cancers such as non-small cell lung cancer (NSCLC) and endometrial cancer. - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing its interaction with VEGF receptors on endothelial cells. This action reduces tumor blood vessel formation, depriving tumors of nutrients and oxygen needed for growth[6][8][10]. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and damage, leading to apoptosis in rapidly dividing cells. - **Ixabepilone** is an epothilone-class microtubule-stabilizing agent that disrupts microtubule dynamics required for cell division, resulting in mitotic arrest and apoptosis[1][3]. The combination has been studied as first-line therapy for advanced NSCLC[1][4] and as an experimental regimen in endometrial cancer[3], among other indications.

Brand names

IxempraParaplatinAvastin

Other names

Ixabepilone and Carboplatin with or without BevacizumabIxabepilone + Carboplatin + Bevacizumab